OBJECTIVE To prepare nanoparticle-based targeting preparation loaded with triptolide （TP）， and evaluate its quality， targeting ability and cytotoxic effects. METHODS Polymer nanoparticles carrying TP-targeted folic acid （FA） receptor （TP@PLGA-PEG-FA） were fabricated using poly （lactic-co-glycolic acid）/polyethylene glycol/FA （PLGA-PEG-FA） as the carrier by emulsion and volatilization technique. The morphology and distribution were observed， and their particle size， Zeta potential， polydispersity index （PDI）， drug loading capacity and encapsulation efficiency were measured. Their stability， blood compatibility， in vitro drug release， uptake by RAW264.7 cells （localization with fluorescent dye Cy3.5）， and in vitro cytotoxicity were evaluated. RESULTS TP@PLGA-PEG-FA exhibited spherical shape and uniform distribution， with particle size of （122.60±0.02） nm， Zeta potential of （－17.6±0.6）mV， and PDI of 0.26±0.02； drug loading capacity and encapsulation efficiency of TP were measured to be （7.78±0.05）% and （68.62±0.03）%， respectively. The hemolysis rates of 100， 200， 300， 400 µg/mL TP@PLGA- PEG-FA were 0.77%， 0.92%， 1.34% and 1.63%， respectively. There were no significant changes in particle size， PDI and Zeta potential when TP@PLGA-PEG-FA were placed in 4 ℃ water for 14 days and in DMEM culture medium containing 10% fetal bovine serum at 37 ℃ for 12 h. The cumulative release rate of TP@PLGA-PEG-FA was （84.83±0.29）% in phosphate buffer at pH5.5 for 72 h， which was significantly higher than the cumulative release rates in phosphate buffer solutions at pH7.4 and 6.5 for 72 h （[ 42.37±0.35）% and （63.83±0.29）% ， respectively] （P＜0.05）. Activated RAW264.7 cells took up significantly more Cy3.5@PLGA-PEG-FA than they took up Cy3.5@PLGA-PEG-FA+free FA and Cy3.5@PLGA-PEG. When the mass concentration of TP was≥15.63 ng/mL， the survival rates of activated cells in the TP@PLGA-PEG-FA groups were significantly lower than those of the same mass concentration of free TP groups （P＜0.05）. CONCLUSIONS The prepared TP@PLGA-PEG-FA has high stability， good blood compatibility， active targeting and cytotoxicity to inflammatory cells.

Objective: To analyze the mediating effect of activities of daily living (ADL) among patients with chronic obstructive pulmonary disease (COPD) on caregiver ability and caregiver burden, so as to provide a basis for improving the quality of care. Methods: From February 2024 to March 2025, COPD patients and their caregivers from the Department of Pulmonary and Critical Care Medicine of a tertiary hospital in Haikou were selected using convenience sampling method. Data on the basic characteristics of both caregivers and patients were collected through questionnaire surveys. The Chinese version of the Family Caregiver Capacity Scale, the Chinese version of the Caregiver Burden Inventory, and the Barthel Index were used to assess caregiver ability, caregiver burden, and patients' ADL, respectively. The mediating effect of ADL among COPD patients on caregiver ability and caregiver burden was analyzed using the Process macro 4.0, with the significance tested via the Bootstrap method. Results: A total of 348 caregivers were surveyed, among whom 274 (78.74%) were females and 74 (21.26%) were males. The majority of caregivers were aged 40 years and above, with 291 individuals (83.62%). The relationship between caregivers and patients was primarily that of being their children, with 185 individuals (53.16%). Correspondingly, 348 COPD patients were surveyed, and the predominant type of medical insurance was the New Rural Cooperative Medical Scheme, with 172 cases (49.43%). The median scores of caregiver ability, caregiver burden, and patients' ADL were 19.00 (interquartile range, 5.00), 47.00 (interquartile range, 8.00) and 45.00 (interquartile range, 15.00) points, respectively. Mediating analysis showed that caregiver ability directly affected caregiver burden, with an effect value of 0.693 (95%CI: 0.553-0.832). It also indirectly affected caregiver burden through the patients' ADL, with an effect value of 0.104 (95%CI: 0.029-0.179). This mediating effect accounted for 13.05% of the total effect. Conclusion The ADL of COPD patients played a mediating role between caregiver ability and caregiver burden, with caregiver ability exerting a significant positive indirect effect on caregiver burden through patients' ADL.

Objective To investigate the effects of menaquinone-4(MK4)on the activation and function of CD8+T cells.Methods An in vitro culture system for primary mouse CD8+T cells was established by isolating these cells from the spleen using CD8a T cell isolation kit.The isolated CD8+T cells were then incubated and activated in a 96-well plate coated with anti-CD3/CD28 antibodies.The impact of MK4 on the activation and cytokine secretion of CD8+T cells was explored by quantifying the expression levels of CD8+T cell activation receptors and cytokines using flow cytometry.Additionally,the concentrations of these cytokines in the culture supernatant were measured by enzyme-linked immunosorbent assay(ELISA).The influence of MK4 on the anti-tumor function of CD8+T cells was evaluated by co-culturing colorectal cancer MC38 cells of mice with CD8+T cells at different ratios,and the effect of MK4 was assessed by detecting tumor cell apoptosis.Results High-purity primary CD8+T cells of mice(97.5％)were isolated using the magnetic bead,which could be activated by pre-coated CD3/CD28 antibodies and showed proliferation.Compared with the control group,the MK4-treated group exhibited increased expressions of CD25,CD69 and CD44 on CD8+T cells,as well as higher production and secretion levels of interleukin-2(IL-2),interferon-γ(IFN-γ),tumor necrosis factor-α(TNF-α)and granzyme B.In addition,CD8+T cells in the MK4-treated group induced a higher percentage of tumor cell apoptosis(36.7％)compared with the control group(29.1％).Conclusion MK4 can enhance the activation of CD8+T cells and promote anti-tumor functions.

Pressure injury (PI) not only reduces the quality of life of patients but also is expensive to manage, placing a heavy financial burden on patients and their families, and society. Despite the increasing diversity of methods used to identify early PI, there are still few methods that can truly and accurately predict early PI. The sub-epidermal moisture scanner is the first U.S. Food and Drug Administration-authorized PI management device that can predict the occurrence and development of PI by measuring the level of local tissue bio-capacitance and monitoring the tissue viability. As an emerging diagnostic instrument, the sub-epidermal moisture scanner has already shown great advantages in clinical practice, which can promote the informatization, digitization, and intelligent prevention and management of PI. This paper introduces the pathophysiological mechanism of PI, elucidates the working principle and parameter settings of the sub-epidermal moisture scanner, its clinical application in monitoring tissue viability in early PI, and its limitation, and looks forward to its future development.

【Objective】 To investigate the frequency of platelet antibodies in voluntary blood donors and patients in Zhongshan, Guangdong Province, and to study the specificity and cross-matching of platelet antibodies. 【Methods】 Platelet antibodies of blood donors and patients were screened by solid-phase immunoadsorption (SPIA), rechecked by flow cytometry (FCM), and antibody specificity was identified by PakPlus enzyme immunoassay, and platelet cross-matching was simulated by SPIA. 【Results】 A total of 1 049 blood donor samples and 598 patient samples were tested, with 6 (0.57%) and 49 (8.19%) samples positive for SPIA,respectively(P<0.05); In SPIA positive samples, the positive concordance rate of FCM in blood donors and patients was 100% vs 95%, and that of enzyme immunoassay was 100% vs 88%. Among the initial screening positive samples of blood donors, 5 were anti-HLA Ⅰ antibodies, accounting for 83%, and 1 was anti CD36 antibody, accounting for 17%, with an incidence rate of 0.10%. Among the 14 samples of enzyme immunoassay positive patients, 2 were anti-GP Ⅱb/Ⅲa, 1 was anti-GP Ⅱa/Ⅱa, 8 were anti HLA Ⅰ, and 3 were mixed antibodies (HLA Ⅰ, GP Ⅱb/Ⅲa, GP Ⅰa/Ⅱa). According to the types of antibodies, HLA Ⅰ antibodies were the most common, accounting for 65% (11/17), followed by HPA related anti GP, accounting for 35% (6/17). The majority of patients had a platelet antibody positive typing rate below 30%, accounting for 71.4% (10/14). 【Conclusions】 The positive rate of platelet antibody of patients in Zhongshan area is significantly higher than that of voluntary blood donors, and most of them are anti-HLA Ⅰ and anti-GP, and the incidence of anti-CD36 is extremely low. Therefore, it is necessary to establish a known platelet antigen donor bank, and at the same time, carry out platelet antibody testing and matching of patients, which is helpful to solve the issue of platelet transfusion refractoriness.

In the field of health,with the innovation drive as the core,the new quality of productivity has successfully gets rid of the shackles of traditional health service delivery mode and industrial development trajectory,showing high-tech,high-efficiency and high-quality characteristics,which is in line with the development concept advocated in the new development stage,representing an advanced productivity quality.In the field of health economics,the new-quality productivity will have a decisive impact on the supply and demand of health services,the allocation and optimization of health resources,health policies and intervention measurement,health system performance and health equity.Meanwhile,the new quality productivity has a profound impact on health economic evaluation and technology evaluation,and even changes the health economic research paradigm.It is undoubtedly an important responsibility and challenge for the health economy research field to give timely and in-depth theoretical discussion on the new quality productivity and actively promote its practical application and development.It requires us to keep up with the pace of the times at the theoretical level and dig deep into the inherent law and value of the new-quality productivity.At the same time,in practice,it is committed to guiding and promoting the effective transformation and implementation of new-quality productivity in the field of health,so as to facilitate the elevation of health economic research and practice to a new qualitative level.

In the field of health,with the innovation drive as the core,the new quality of productivity has successfully gets rid of the shackles of traditional health service delivery mode and industrial development trajectory,showing high-tech,high-efficiency and high-quality characteristics,which is in line with the development concept advocated in the new development stage,representing an advanced productivity quality.In the field of health economics,the new-quality productivity will have a decisive impact on the supply and demand of health services,the allocation and optimization of health resources,health policies and intervention measurement,health system performance and health equity.Meanwhile,the new quality productivity has a profound impact on health economic evaluation and technology evaluation,and even changes the health economic research paradigm.It is undoubtedly an important responsibility and challenge for the health economy research field to give timely and in-depth theoretical discussion on the new quality productivity and actively promote its practical application and development.It requires us to keep up with the pace of the times at the theoretical level and dig deep into the inherent law and value of the new-quality productivity.At the same time,in practice,it is committed to guiding and promoting the effective transformation and implementation of new-quality productivity in the field of health,so as to facilitate the elevation of health economic research and practice to a new qualitative level.

In the field of health,with the innovation drive as the core,the new quality of productivity has successfully gets rid of the shackles of traditional health service delivery mode and industrial development trajectory,showing high-tech,high-efficiency and high-quality characteristics,which is in line with the development concept advocated in the new development stage,representing an advanced productivity quality.In the field of health economics,the new-quality productivity will have a decisive impact on the supply and demand of health services,the allocation and optimization of health resources,health policies and intervention measurement,health system performance and health equity.Meanwhile,the new quality productivity has a profound impact on health economic evaluation and technology evaluation,and even changes the health economic research paradigm.It is undoubtedly an important responsibility and challenge for the health economy research field to give timely and in-depth theoretical discussion on the new quality productivity and actively promote its practical application and development.It requires us to keep up with the pace of the times at the theoretical level and dig deep into the inherent law and value of the new-quality productivity.At the same time,in practice,it is committed to guiding and promoting the effective transformation and implementation of new-quality productivity in the field of health,so as to facilitate the elevation of health economic research and practice to a new qualitative level.

In the field of health,with the innovation drive as the core,the new quality of productivity has successfully gets rid of the shackles of traditional health service delivery mode and industrial development trajectory,showing high-tech,high-efficiency and high-quality characteristics,which is in line with the development concept advocated in the new development stage,representing an advanced productivity quality.In the field of health economics,the new-quality productivity will have a decisive impact on the supply and demand of health services,the allocation and optimization of health resources,health policies and intervention measurement,health system performance and health equity.Meanwhile,the new quality productivity has a profound impact on health economic evaluation and technology evaluation,and even changes the health economic research paradigm.It is undoubtedly an important responsibility and challenge for the health economy research field to give timely and in-depth theoretical discussion on the new quality productivity and actively promote its practical application and development.It requires us to keep up with the pace of the times at the theoretical level and dig deep into the inherent law and value of the new-quality productivity.At the same time,in practice,it is committed to guiding and promoting the effective transformation and implementation of new-quality productivity in the field of health,so as to facilitate the elevation of health economic research and practice to a new qualitative level.

In the field of health,with the innovation drive as the core,the new quality of productivity has successfully gets rid of the shackles of traditional health service delivery mode and industrial development trajectory,showing high-tech,high-efficiency and high-quality characteristics,which is in line with the development concept advocated in the new development stage,representing an advanced productivity quality.In the field of health economics,the new-quality productivity will have a decisive impact on the supply and demand of health services,the allocation and optimization of health resources,health policies and intervention measurement,health system performance and health equity.Meanwhile,the new quality productivity has a profound impact on health economic evaluation and technology evaluation,and even changes the health economic research paradigm.It is undoubtedly an important responsibility and challenge for the health economy research field to give timely and in-depth theoretical discussion on the new quality productivity and actively promote its practical application and development.It requires us to keep up with the pace of the times at the theoretical level and dig deep into the inherent law and value of the new-quality productivity.At the same time,in practice,it is committed to guiding and promoting the effective transformation and implementation of new-quality productivity in the field of health,so as to facilitate the elevation of health economic research and practice to a new qualitative level.